Details of the Drug

General Information of Drug (ID: DMKXJZ7)

Drug Name
Suprofen
Synonyms
Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure
Indication
Disease Entry ICD 11 Status REF
Miosis LA11.62 Approved [1], [2], [3]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 260.31
Topological Polar Surface Area (xlogp) 3.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Bioavailability
92% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.76 mL/min/kg [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.1 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 65.8555 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.006% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.04 L/kg [5]
Chemical Identifiers
Formula
C14H12O3S
IUPAC Name
2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
Canonical SMILES
CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
InChIKey
MDKGKXOCJGEUJW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5359
ChEBI ID
CHEBI:9362
CAS Number
40828-46-4
DrugBank ID
DB00870
TTD ID
D07BPS
INTEDE ID
DR1520

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Miosis
ICD Disease Classification LA11.62
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Suprofen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Suprofen and Inotersen. Amyloidosis [5D00] [39]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Suprofen and Cilostazol. Arterial occlusive disease [BD40] [39]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Suprofen and Anisindione. Coagulation defect [3B10] [39]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Suprofen and Regorafenib. Colorectal cancer [2B91] [39]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Suprofen and Ardeparin. Coronary thrombosis [BA43] [39]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Suprofen and Danaparoid. Deep vein thrombosis [BD71] [39]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Suprofen and Rivaroxaban. Deep vein thrombosis [BD71] [39]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Suprofen and Tazemetostat. Follicular lymphoma [2A80] [39]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Suprofen and Avapritinib. Gastrointestinal stromal tumour [2B5B] [39]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Suprofen and Dipyridamole. Hypertension [BA00-BA04] [39]
PF-06463922 DMKM7EW Moderate Increased metabolism of Suprofen caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Suprofen and Acalabrutinib. Mature B-cell lymphoma [2A85] [39]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Suprofen and Ibrutinib. Mature B-cell lymphoma [2A85] [39]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Suprofen and Ponatinib. Mature B-cell lymphoma [2A85] [39]
Panobinostat DM58WKG Moderate Increased risk of bleeding by the combination of Suprofen and Panobinostat. Multiple myeloma [2A83] [39]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Suprofen and Ruxolitinib. Myeloproliferative neoplasm [2A20] [39]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Suprofen and Dasatinib. Myeloproliferative neoplasm [2A20] [39]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Suprofen and Prasugrel. Myocardial infarction [BA41-BA43] [39]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Suprofen and Vorapaxar. Myocardial infarction [BA41-BA43] [39]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Suprofen caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [41]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Suprofen and Epoprostenol. Pulmonary hypertension [BB01] [39]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Suprofen and Iloprost. Pulmonary hypertension [BB01] [39]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Suprofen and Plicamycin. Testicular cancer [2C80] [39]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Suprofen and Cangrelor. Thrombosis [DB61-GB90] [39]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Suprofen and Brilinta. Thrombosis [DB61-GB90] [39]
Cabozantinib DMIYDT4 Moderate Increased risk of bleeding by the combination of Suprofen and Cabozantinib. Thyroid cancer [2D10] [39]
⏷ Show the Full List of 26 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7298).
2 Drug information of Suprofen, 2008. eduDrugs.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
9 Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab Dispos. 2003 Nov;31(11):1369-77.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
12 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
13 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
14 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
15 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
16 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
17 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
18 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
19 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
20 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
21 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
22 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
23 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
24 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
25 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
26 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
27 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
28 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
29 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
30 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
31 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
32 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
33 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
34 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
35 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
36 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
37 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
38 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
39 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
40 Cerner Multum, Inc. "Australian Product Information.".
41 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.